Therapy News and Research

RSS

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied.

18 Nov 2010

New technique to identify cancer biomarkers

The University of Liège has presented TARGETOME, the most recent of its spin-offs, which is also the first to spring from its applied geno-proteomics centre, GIGA.

18 Nov 2010

Multiple pain locations contribute to greater knee pain

A new study found that patients with osteoarthritis (OA) of the knee who also have pain in other joints were more likely to experience greater knee pain. Specifically, pain in the lower back as well as foot pain and elbow pain on the same side as the affected knee were associated with more severe knee pain. Full details appear in the December issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2010.

18 Nov 2010

Accentia and Biovest exit Chapter 11 as fully restructured organizations

Accentia Biopharmaceuticals, Inc. announced that, effective today, the Company and its majority-owned subsidiary, Biovest International, Inc., have both successfully completed their reorganizations. Pursuant to their respective Plans of Reorganization approved by the bankruptcy court, Accentia and Biovest have now formally exited Chapter 11 as fully restructured organizations.

18 Nov 2010

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.

18 Nov 2010

COPD Biomarkers Qualification Consortium launched

The COPD Foundation announces the launch of an unprecedented collaborative effort to pool information on Chronic Obstructive Pulmonary Disease (COPD): the COPD Biomarkers Qualification Consortium (CBQC). The CBQC brings together government agencies, academic institutions and pharmaceutical companies that will share research data on COPD biomarkers—indicators of disease progression/severity.

18 Nov 2010

Statins activate bacterial-killing properties of white blood cells

Widely prescribed for their cholesterol-lowering properties, recent clinical research indicates that statins can produce a second, significant health benefit: lowering the risk of severe bacterial infections such as pneumonia and sepsis.

18 Nov 2010

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced achievement of a US$4.0 million milestone payment from its development partner, Endo Pharmaceuticals Inc. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009.

18 Nov 2010

BioSante announces sale of oncolytic virus technology to Cold Genesys

BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.

18 Nov 2010

Researchers are revolutionizing treatment of cardiovascular disease through regenerative stem cell therapy

Northwestern Medicine physician researchers are revolutionizing treatment of cardiovascular disease by utilizing patients' own stem cells to regenerate heart and vascular tissue.

18 Nov 2010

Regado presents poster on REG3 at AHA Scientific Sessions meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Imec and PEIRA develop platform for in-vitro study of brain tissue

The nanoelectronics research centre imec and Peira, a Belgium-based manufacturer of pharmaceutical and chemical research instruments, jointly developed an innovative slice-tilting instrument for in-vitro research on brain tissue. The new tool enables long-term studying of brain cultures through electronic stimulation and read-out, essential in getting insight into the functioning of the brain.

17 Nov 2010

13-hour lifesaving heart/liver transplant performed on pulmonary atresia patient

A 28-year old man from Georgia, David Krech, is recovering from a rare, lifesaving heart/liver transplant on October 15 at the University of Maryland Medical Center. The 13-hour operation followed a five-month journey as he awaited a suitable heart and liver donor.

17 Nov 2010

Health professionals invited for 1st Asia-Pacific Osteoporosis Meeting

Healthcare providers in the Asia-Pacific region are coping with a rising tide of osteoporotic fractures. The IOF Regionals - 1st Asia- Pacific Osteoporosis Meeting, to take place in Singapore from December 10-13, 2010, is an ideal opportunity for health professionals in the region to acquire the latest practical information on osteoporosis and related fractures.

17 Nov 2010

St. Jude organizes tobacco cessation program for cancer survivors who smoke

Cancer survivors who smoke and need help quitting can receive help through a tobacco cessation program organized by St. Jude Children's Research Hospital.

17 Nov 2010

Therapy News and Research

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Researchers report results from Phase III DEFINE study for coronary heart disease

New technique to identify cancer biomarkers

Multiple pain locations contribute to greater knee pain

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Accentia and Biovest exit Chapter 11 as fully restructured organizations

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

COPD Biomarkers Qualification Consortium launched

Statins activate bacterial-killing properties of white blood cells

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

BioSante announces sale of oncolytic virus technology to Cold Genesys

Researchers are revolutionizing treatment of cardiovascular disease through regenerative stem cell therapy

Regado presents poster on REG3 at AHA Scientific Sessions meeting

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Imec and PEIRA develop platform for in-vitro study of brain tissue

13-hour lifesaving heart/liver transplant performed on pulmonary atresia patient

Health professionals invited for 1st Asia-Pacific Osteoporosis Meeting

St. Jude organizes tobacco cessation program for cancer survivors who smoke

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News